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The role of radiotherapy in the treatment of 
superficial soft- tissue sarcomas
Aims
The existing clinical guidelines do not describe a clear indication for adjuvant radiotherapy 
(RT) in the treatment of superficial soft tissue sarcomas (STSs). We aimed to determine the 
efficacy of adjuvant RT for superficial STSs.
Methods
We retrospectively studied 304 patients with superficial STS of the limbs and trunk who 
underwent surgical resection at a tertiary sarcoma centre. The efficacy of RT was investi-
gated according to the tumour size and grade: group 1, ≤ 5 cm, low grade; group 2, ≤ 5cm, 
high grade; group 3, > 5 cm, low grade; group 4, > 5 cm, high grade.
Results
The five- and ten- year local recurrence- free survival (LRFS) for all patients was 88% and 
81%, respectively. While the efficacy of adjuvant RT was not proven in local control of all 
patients (five- year LRFS; RT+, 90% versus RT-, 83%; p = 0.074), the LRFS was significantly 
improved by adjuvant RT in group 2 (five- year LRFS; RT+, 96% versus RT-, 82%; p = 0.019), 
and group 4 (five- year LRFS; RT+, 87% versus RT-, 73%; p = 0.027). In groups 2 and 4, adju-
vant RT significantly reduced the LR risk if the resection margin was clear but less than 5 
mm; the LR rate was 7% with adjuvant RT compared with 26% with surgery alone  
(p = 0.003). There was no statistical relationship with the use of adjuvant RT and survival in 
every group.
conclusion
Adjuvant RT reduces the risk of local recurrence in patients with superficial high- grade STS 
regardless of tumour size, especially when resection margin is less than 5 mm.
cite this article: Bone Joint J 2020;102-B(8):1088–1094.
Introduction
Soft tissue sarcomas (STSs) constitute a diverse 
group of malignant mesenchymal tumours with 
over 50 histological entities described.1-3 The 
primary treatment of localized STSs is surgical 
resection, but may involve multimodal treatment, 
which may include radiotherapy (RT) and/or 
chemotherapy. The resection margin is generally 
accepted as a factor for predicting local recur-
rence (LR), although the adequacy of margin 
width is controversial.4 The efficacy of adjuvant 
RT in the treatment of STSs was demonstrated 
in a prospective randomized trial,5 although the 
tumour location, superficial or deep, was not 
described. Currently, several guidelines such 
as the European Society for Medical Oncology 
(ESMO)6 and National Comprehensive Cancer 
Network (NCCN) Clinical Practice Guidelines 
(http://www. nccn. org) advocate that RT should 
be considered for high- grade, deep tumours > 5 
cm in size.
However, the efficacy of adjuvant RT for 
superficial STSs has rarely been discussed. The 
ESMO guidelines do not offer a definitive RT 
indication for tumours other than high- grade, 
deep, tumours > 5 cm in maximum dimension. 
They state that the decision should be deter-
mined in a multidisciplinary fashion.2 Thus, 
the question remains whether or not there is a 
benefit from administering RT in the treatment 
of superficial STSs. This study was conducted 
to investigate the efficacy of adjuvant RT for 
these tumours.
Methods
We conducted a retrospective study of patients 
with superficial STSs who underwent surgical 
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Table I. Patient demographics.
Variables Total Group 1: ≤ 5 cm,  
low grade
Group 2: ≤ 5 cm,  
high grade
Group 3: > 5 cm,  
low grade
Group 4: > 5 cm,  
high grade
Total patients, n (%) 304 19 (1) 90 (30) 14 (5) 181 (60)
Median age, yrs (range) 65 (8 to 99) 48 (26 to 82) 65 (8 to 94) 50 (35 to 89) 66 (11 to 99)
Sex, n (%)
Male 157 (52) 8 (42) 53 (59) 13 (93) 83 (46)
Female 147 (48) 11 (58) 37 (41) 1 (7) 98 (54)
Site, n (%)
Lower limb 183 (60) 9 (47) 53 (59) 7 (50) 114 (63)
Upper limb 61 (20) 4 (21) 25 (28) 2 (14) 30 (17)
Trunk 60 (20) 6 (32) 12 (13) 5 (36) 37 (20)
Diagnosis, n (%)
Undifferentiated sarcoma 134 (41) 7 (37) 41 (46) 1 (7) 85 (47)
Myxofibrosarcoma 47 (15) 1 (5) 13 (14) 1 (7) 32 (18)
Leiomyosarcoma 29 (10) 4 (21) 14 (16) 0 (0) 11 (6)
Myxoid liposarcoma 25 (8) 2 (11) 5 (6) 4 (29) 14 (8)
Pleomorphic liposarcoma 10 (3) 0 (0) 0 (0) 0 (0) 10 (6)
Angiosarcoma 9 (3) 0 (0) 2 (2) 0 (0) 7 (4)
Synovial sarcoma 9 (3) 1 (5) 4 (4) 0 (0) 4 (2)
MPNST 7 (2) 0 (0) 1 (1) 0 (0) 6 (3)
Others 34 (11) 4 (21) 10 (11) 8 (57) 12 (7)
Adjuvant radiotherapy,  
n (%)
Yes 210 (69) 1 (5) 58 (64) 2 (14) 149 (82)
No 94 (31) 18 (95) 32 (36) 12 (86) 32 (18)
Margin, n (%)
Intralesional 46 (15) 1 (5) 11 (12) 3 (21) 31 (17)
Marginal 158 (52) 9 (47) 42 (47) 9 (64) 98 (54)
Wide 94 (31) 10 (53) 33 (37) 2 (14) 49 (27)
Radical 6 (2) 0 (0) 3 (3) 0 (0) 3 (2)
Local recurrence, n (%)
Yes 35 (12) 2 (11) 5 (6) 1 (7) 27 (15)
No 269 (88) 17 (89) 85 (94) 13 (93) 154 (85)
MPNST, malignant peripheral nerve sheath tumour.
resection at a tertiary sarcoma centre between April 1996 
and December 2015. Patients who were referred after inad-
vertent excisions at another hospital, that underwent re- ex-
cision after primary resection, received any chemotherapy, 
or were diagnosed as atypical lipomatous tumour/well- 
differentiated liposarcoma were excluded. A total of 304 
patients met the inclusion criteria for the study. The details 
of demographic and treatment data are shown in Table I. The 
median age at diagnosis was 65 years (interquartile range 
(IQR) 52 to 76). There was a slight predominance of males 
(n = 157/304; 52%).
All the patients were discussed at a multidisciplinary team 
meeting and the final management plan was developed. The 
decision to use RT was individualized and variable but in 
general RT was advised for patients with high- grade and large 
tumours, close or contaminated surgical margins, or tumours 
located in areas where LR would be difficult to manage after 
resection, such as in the axilla. Tumour grade was classified 
according to the French Federation of Cancer Centres Sarcoma 
Group (FNCLCCs) grading system7,8 by pathologists expe-
rienced in evaluating STSs; groups with a high- grade tumour 
included grade 2 and grade 3 tumours and groups with a low- 
grade tumour included grade 1 tumour by the FNCLCC grading 
system.
This study was approved by the institutional review board 
and all data were collected from the clinical and pathological 
data from an institutional prospective sarcoma database at a 
single tertiary centre.
Statistical analysis. Outcome measures studied included local- 
recurrence free survival (LRFS) and disease- specific survival 
(DSS). The Kaplan- Meier method was used to determine LRFS 
and DSS with time zero defined as the date of diagnosis and 
censored at the date of last follow- up or LR and tumour- related 
death, respectively. Univariate analysis was performed compar-
ing groups with log- rank test and significant variables under-
went subsequent multivariate Cox proportional hazard analysis 
to identify predictors of LRFS and DSS. The variables of each 
group were compared with use of the chi- squared test or the 
Fisher’s exact test. A p- value ≤ 0.05 was considered significant. 
Statistical analyses were conducted using SPSS v. 23 (IBM, 
Armonk, New York, USA).
Results
Demographic and treatment details. In our series, more than 
half of the tumours were located in the lower limb (n = 183/304; 
60%), followed by upper limb (n = 61/304; 20%), and trunk (n 
= 60/304; 20%). The histological diagnosis was undifferentiated 
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Fig. 1
Kaplan- Meier curves showing local recurrence- free survival in all 
patients stratified by the use of adjuvant radiotherapy (RT). p = 0.074, 
log- rank test.
sarcoma in 134 patients (41%), myxofibrosarcoma in 47 (15%), 
leiomyosarcoma in 29 (10%), myxoid liposarcoma in 25 (8%), 
pleomorphic liposarcoma in ten (3%), angiosarcoma in nine (3%), 
synovial sarcoma in nine (3%), malignant peripheral sheath tu-
mour in seven (2%), and others in 34 (11%). Most tumours were 
high grade (n = 271/304; 90%) and the median tumour size was 
6.3 cm (IQR 4.7 to 9.0). RT was administered to 210 (69%) pa-
tients with 206 of these receiving it postoperatively, four had 
preoperative RT and one patient received preoperative RT with 
a postoperative boost. After treatment, patients with high- grade 
tumours were followed every three to four months in the first two 
or three years, then twice a year up to the fifth year, and once a 
year thereafter up to ten years postoperatively, with clinical ex-
amination and chest radiographs on each visit. Patients with low- 
grade tumours were followed in a similar way but every four to six 
months, in the first three to five years, then annually. The median 
follow- up period was 53 months (IQR 19 to 81 months), which 
was similar between groups.
Based on the tumour size and grade, patients were divided 
into four groups (Table I); ≤ 5 cm and low- grade tumours (group 
1); ≤ 5 cm, high- grade tumours (group 2); > 5 cm, low- grade 
tumours (group 3); and > 5 cm, high- grade tumours (group 4).
Local tumour control according to tumour size and grade. 
Surgical margins were negative in 258 patients (85%) and 
positive in 46 (15%). LR occurred in 35 patients (12%). The 
five- and ten- year LRFS for all patients was 88% and 81%, re-
spectively. In the univariate analysis, tumour size > 5 cm (p = 
0.023, log- rank test) and positive resection margin (p < 0.001, 
log- rank test) were significant prognostic factor for LRFS 
(Supplementary Fig. a). There was a trend toward better local 
control in patients with adjuvant RT (p = 0.074, log rank test); 
the five- and ten- year LRFS was 94% and 84% in patients with 
adjuvant RT and 84% and 77% in those without it (Figure 1). 
In the multivariate analysis, tumour size (> 5 cm hazard ra-
tio (HR) 2.405; 95% confidence interval (CI) 1.024 to 5.646; 
p = 0.044 vs ≤ 5 cm HR 1), surgical margin (positive, 3.286; 
95% CI 1.635 to 6.602; p = 0.001 vs negative HR, 1), and 
use of adjuvant RT (RT- HR, 2.960; 95% CI 1.463 to 5.987; 
p = 0.003 vs RT+ HR, 1) were independent prognostic predic-
tors for LRFS (Table II).
In group 1 (≤ 5 cm, low- grade tumours; n = 19), surgical 
margin was negative in 18 patients (95%) and positive in one 
(5%). LR occurred in two (11%) patients and the five- and 
ten- year LRFS was 93% and 83%, respectively (Figure 2). No 
patient treated with RT (n = 0/1) developed LR compared to 
11% (n = 2/18) of those who did not have RT, but the differ-
ence was not statistically significant due to limited number of 
patients (p = 0.673, log- rank test; Figure 3a, Table III).
In group 2 (≤ 5 cm, high- grade tumours; n = 90), resection 
margin was negative in 79 patients (88%) and positive in 11 
(12%). The five- and ten- year LRFS was 92% at both inter-
vals (Figure 2). LR occurred in five patients (5%) including one 
patient with RT and four without RT. The LRFS was signifi-
cantly better in patients treated with adjuvant RT than those 
without it (p = 0.019, log- rank test; Figure 3b, Table III).
In group 3 (> 5 cm, low- grade tumours; n = 14), LR occurred 
in one patient (7%) who had positive margin but declined 
further treatment. The five- and ten- year LRFS was 100% and 
88%, respectively (Figure 2). There was no significant differ-
ence in LRFS between patients with or without adjuvant RT 
(p = 0.564, log- rank test; Figure 3c, Table III).
In group 4 (> 5 cm, high- grade tumours; n = 181), LR 
occurred in 27 patients (17%). This included 11 patients with 
a positive margin and 16 who had a negative margin, respec-
tively. Among these patients, 18 patients had adjuvant RT 
and nine did not. The five- and ten- year LRFS was 84% and 
76%, respectively (Figure 2). LRFS was significantly better in 
patients treated with adjuvant RT than without it (p = 0.027, 
log- rank test; Figure 3d, Table III).
local control according to use of adjuvant RT and measured 
resection margins. The width of surgical margins was clearly 
described for 282 patients (93%) of the patients studied. The 
relationship between resection margin width and LR stratified 
according to use of adjuvant RT is shown in Tables IV and V, 
and Supplementary Table i, ii.
In high- grade tumours, the LR rate in tumours with a posi-
tive resection margin was lower in patients with adjuvant RT 
than those without it, despite no significant difference; 21% 
and 38%, respectively (p = 0.374, chi- squared test). In tumours 
resected with a clear margin, adjuvant RT significantly reduced 
the LR rate if the resection margin was less than 5 mm; 7% 
with and 26% without adjuvant RT (p = 0.003, chi- squared test; 
Table IV). However, the LR rate was similar in tumours with 
and without adjuvant RT if the resection margin was over 5 
mm; 6% and 5%, respectively (p = 0.400, chi- squared test). The 
histological subtypes for patients with margins over 5 mm who 
developed LR were myxofibrosarcoma (n = 1; RT+) and undif-
ferentiated pleomorphic sarcoma (UPS) (n = 1; RT-).
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Table II. Multivariate analysis for local recurrence- free survival and disease- specific survival.
Variable LRFS DSS
HR (95% CI) p- value HR (95% CI) p- value
Size 0.044 0.006
≤ 5 cm 1 1
> 5 cm 2.405 (1.024 to 5.646) 2.286 (1.261 to 4.143)
grade 0.071 0.034
Low 1 1
High 2.578 (0.746 to 8.908) 8.790 (1.176 to 65.689)
Radiotherapy 0.003 0.555
Yes 1 1
No 2.960 (1.463 to 5.987) 0.834 (0.457 to 1.522)
Resection margin 0.001 0.412
Negative 1 1
Positive 3.286 (1.635 to 6.602) 1.271 (0.717 to 2.252)
CI, confidence interval; DSS, disease- specific survival; HR, hazard ratio; LRFS, local recurrence- free survival.
Fig. 2
Kaplan- Meier curves showing local recurrence- free survival in all 
patients stratifying by tumour size and grade (p = 0.102). *p = 0.024 
(compared to group 2), log- rank test.
In low- grade tumours, no LR occurred in the three patients 
treated with adjuvant RT. Of those who did not received adju-
vant RT, LR occurred in two of three patients (67%) with posi-
tive margin and one of 13 patients (8%) with margin less than 2 
mm (Table V). The efficacy of adjuvant RT did not reach statis-
tical significance (p = 0.629, chi- squared test).
Survival outcome. The five- and ten- year DSS for all pa-
tients was 75% and 66%, respectively. Univariate analysis 
revealed that the tumour size over 5 cm, high grade, and the 
presence of LR were significantly associated with poorer DSS 
(Supplementary Figure b). The five- and ten- year DSS was 
100%, 100% for group 1, 86%, 76% for group 2, 100%, 76% 
for group 3, and 64%, 55% for group 4. Although there was 
a trend toward better survival in patients with clear resection 
margin, it did not reach statistical difference in DSS (p = 0.177, 
log- rank test). The efficacy of adjuvant RT for DSS was not 
proven in every group (Supplementary Figure c). The multivar-
iate analysis revealed that tumour size (> 5 cm HR, 2.286; 95% 
CI 1.261 to 4.143; p = 0.006 vs ≤ 5 cm HR, 1), grade (high HR, 
8.790; 95% CI 1.176 to 65.689; p = 0.034 vs low HR, 1), and 
the presence of LR (present HR, 3.137; 95% CI, 1.818 to 5.415; 
p < 0.001 vs absent HR, 1) were independent prognostic factors 
for DSS (Table II).
Discussion
There is no consensus whether or not the use of adjuvant RT 
provides benefit for patients with superficial STS, while the 
efficacy of adjuvant RT is proven in other types of sarcomas 
such as Ewing sarcoma.9 In a study of 367 patients from the 
French Sarcoma Group database, the use of adjuvant RT had 
no significant correlation with LRFS and overall survival.10 In 
contrast, Rydholm et al11 and Tsagozis et al12 indicated the effi-
cacy of adjuvant RT in local control. Rydholm et al11 reviewed 
129 patients with superficial STSs and reported that the LR rate 
was 11% (n = 1/9) and 67% (n = 22/33) for marginal resections 
with and without adjuvant RT, respectively. In a report from 
Scandinavian Sarcoma Group, Tsagozis et al12 demonstrated 
that LR rate was 7% (n = 8/115) in patients with adjuvant RT 
and 12% (n = 36/298) in those without it, but there was no anal-
ysis regarding tumour size. In our study, we identified that adju-
vant RT significantly reduced the risk of LR in patients with 
superficial high- grade STSs regardless of tumour size. These 
outcomes confirm the positive efficacy of adjuvant RT for high- 
grade, superficial STS.
To date, the significance of resection margin width according 
to the use of adjuvant RT in superficial STSs has been unknown. 
In the study by the Scandinavian Sarcoma Group, adjuvant RT 
was associated with a superior local control in patients with 
high- grade tumours and marginal margin.12 However, the clas-
sification of margins categorized as radical, wide, marginal, and 
intralesional by Enneking et al,13 is inherently subjective and 
the answer to the question of what is a marginal margin varies 
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Fig. 3
a) Kaplan- Meier curves showing local recurrence- free survival stratified by the use of adjuvant radiotherapy (RT) in group 1 (≤ 5 cm, low- grade);  
p = 0.673. b) Kaplan- Meier curves showing local recurrence- free survival stratified by the use of adjuvant radiotherapy in group 2 (≤ 5 cm, high- 
grade); p = 0.019, c) Kaplan- Meier curves showing local recurrence- free survival stratified by the use of adjuvant radiotherapy in group 3 (> 5 cm, 
low- grade); p = 0.564. d) Kaplan- Meier curves showing local recurrence- free survival stratified by the use of adjuvant radiotherapy in group 4 (> 5 
cm, high- grade); p = 0.027, log- rank test.
depending on the surgeons and investigators. In our study, adju-
vant RT significantly reduced the LR rate of high- grade STSs 
if the resection margin was less than 5 mm. The efficacy of 
adjuvant RT was not evident if the resection margin was over 
5 mm. The histological subtypes associated with LR despite a 
margin greater than 5 mm were myxofibrosarcoma and UPS. 
Myxofibrosarcoma and UPS frequently present an infiltrative 
growth pattern,14-17 and the difficulty in local control even in the 
patients with wide resection margins has been noted.15,16 Thus, 
adjuvant RT may contribute to decreased LR risk regardless of 
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Table III. Local recurrence- free survival according to use of radiotherapy.
groups by tumour size and grade Adjuvant RT- Adjuvant RT+ p- value*
n 5- yr, % 10- yr, % n 5- yr, % 10- yr, %
Group 1: ≤ 5 cm, low grade 18 93 83 1 100 100 0.673
Group 2: ≤ 5 cm, high grade 32 82 82 58 96 96 0.019
Group 3: > 5 cm, low grade 12 100 83 2 100 100 0.564
Group 4: > 5 cm, high grade 32 73 66 149 87 78 0.027
*Log- rank test.
RT, radiotherapy.
Table IV. Local recurrence rate in patients with superficial high- grade soft- tissue sarcoma stratified by resection margin in millimetres.
closest margin Total Adjuvant RT- Adjuvant RT+ p- value*
LR+, n Total, n LR, % LR+, n Total, n LR, % LR+, n Total, n LR, %
0 mm 11 46 24 3 8 38 8 38 21 0.374
0.1 to 4.9 mm 18 175 10 8 31 26 10 144 7 0.003
≥ 5.0 mm 2 35 6 1 19 5 1 16 6 0.400
Total 31 256 13 12 58 21 19 198 5 0.038
*Chi- squared test.
LR, local recurrence; RT, radiotherapy.
Table V. Local recurrence rate in patients with superficial low- grade soft- tissue sarcoma stratified by resection margin in millimetres.
closest margin Total Adjuvant RT- Adjuvant RT+ p- value*
LR+, n Total, n LR, % LR+, n Total, n LR, % LR+, n Total, n LR, %
0 mm 2 4 50 2 3 67 0 1 0 0.600
0.1 to 1.9 mm 1 14 7 1 13 8 0 1 0 0.929
≥ 2.0 mm 0 9 0 0 7 0 0 1 0 N/A
Total 3 26 12 3 23 13 0 3 0 0.629
*Chi- squared test.
LR, local recurrence; N/A, not applicable; RT, radiotherapy
the margin extent for myxofibrosarcoma and UPS, considering 
their local aggressiveness by infiltrative behaviour, although the 
radio- responsiveness of these tumours may not be the same as 
other histiotypes.15,18
The rate of LR and tumour- related death in this study was 
comparable to the previously published results. The reported 
LR rates were 9% to 23%10,12,19,20 and five- year overall survival 
were 75% to 81%.10,12,20 In general, superficial STSs are associ-
ated with superior survival compared to deep- seated STSs.21,22 
Tsagozis et al12 described that the good prognosis of superfi-
cial STSs could be attributed to the low proportion of patients 
presenting with metastatic disease, which is lower than the 
rate of patients with deep- seated STSs. The rate of metastatic 
disease at presentation was 5% (n = 12/222) in their study, 
while the reported rate in deep- seated STSs was 8%.
The prognostic significance of adjuvant RT in STSs has 
been unclear. A retrospective study from the Surveillance, 
Epidemiology, and End Results (SEER) database with 6,960 
patients with high- grade STSs involving the extremities found 
that three- year overall survival was increased by up to 10% (p 
< 0.001) with RT,23,24 although randomized trials of adjuvant 
external- beam RT have not confirmed this survival benefit.24 For 
superficial STSs, no study has demonstrated a survival benefit 
of adjuvant RT.10-12 In this study, we observed no survival differ-
ence between patients treated with or without adjuvant RT in 
both low- grade and high- grade tumours. Collectively, adjuvant 
RT seems to be beneficial for local control but not for survival 
in patients with superficial STS.
We acknowledge several limitations to this study. Firstly, 
this study has a retrospective nature. Secondly, the number of 
patients, especially with low- grade STS, was relatively small 
for statistical analysis. Further analysis based on the larger 
cohorts would clarify the efficacy of adjuvant RT for low- grade 
tumours. Thirdly, the details regarding RT including radiation 
field and dose were unavailable for analysis, as RT is adminis-
tered outside our institution. Fourthly, RT- related complications 
were not fully documented because of the reasons above and 
could not be discussed. Fifthly, this study did not compare func-
tional outcomes between patients who received RT to those who 
did not. The reason is that the tumour sites varied from upper 
limb, lower limb, to trunk wall, and the extent of the resec-
tion also varied according to the tumour size and surrounding 
tissues, which made it difficult to perform a precise comparison 
between patients with and without the use of RT. Lastly, this 
study has an inherent selection bias in terms of the RT- treated 
patients as there was no randomization. In the absence of clear 
guidance regarding RT in superficial STSs, patients receiving 
RT were deemed to be high risk by the multidisciplinary team 
meeting. This could be a possible confounding factor in inter-
preting the outcomes of RT.
In conclusion, this study confirmed the efficacy of adjuvant 
RT in local control for high- grade superficial STSs regardless 
of the tumour size. LR risk was significantly reduced by adju-
vant RT if the resection margin was less than 5 mm. The use of 
adjuvant RT had no relationship with tumour- related mortality 
in patients with superficial STS.
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Take home message
  - Adjuvant radiotherapy reduces the risk of local recurrence 
in patients with superficial high- grade STS regardless of the 
tumour size.
  - The risk of local recurrence in superficial high- grade STSs is reduced 
by adjuvant radiotherapy, when the resection margin is less than 5 mm.
Supplementary material
  Further Kaplan–Meier curves showing LRFS and DSS 
stratified by tumour- and treatment- related variables, 
and more detailed information on the LR rate according 
to the resection margin in millimetres.
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